Loading...
Please wait, while we are loading the content...
Similar Documents
The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial
| Content Provider | Scilit |
|---|---|
| Author | Aziz, Tavga Ahmed Hussain, Saad Abdulrahman Mahwi, Taha Othman Ahmed, Zheen Aorahman Rahman, Heshu Sulaiman Rasedee, Abdullah |
| Copyright Year | 2018 |
| Abstract | The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial Tavga Ahmed Aziz,1 Saad Abdulrahman Hussain,2 Taha Othman Mahwi,3 Zheen Aorahman Ahmed,1 Heshu Sulaiman Rahman,4–6 Abdullah Rasedee6 1Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaimani City, 2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Rafidain University, Baghdad, 3Department of Medicine, College of Medicine, 4Department of Clinic and Internal Medicine, College of Veterinary Medicine, University of Sulaimani, 5Department of Medical Laboratory Sciences, College of Health Sciences, Komar University of Science and Technology, Chaq-Chaq-Qularaisi, Sulaimani City, Iraq; 6Department of Veterinary Laboratory Diagnosis, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Selangor, Malaysia Background and aim: Type 2 diabetes mellitus (T2DM) is one of the major diseases confronting the health care systems. In diabetes mellitus (DM), combined use of oral hypoglycemic medications has been shown to be more effective than metformin (Met) alone in glycemic control. This study determined the effects of Ginkgo biloba (GKB) extract as an adjuvant to Met in patients with uncontrolled T2DM.Subjects and methods: Sixty T2DM patients were recruited in a randomized, placebo-controlled, double-blinded, and multicenter trial. The patients, currently using Met, were randomly grouped into those treated with either GKB extract (120 mg/day) or placebo (starch, 120 mg/day) for 90 days. Blood glycated hemoglobin (HbA1c), fasting serum glucose, serum insulin, body mass index (BMI), waist circumference (WC), insulin resistance, and visceral adiposity index (VAI) were determined before (baseline) and after 90 days of GKB extract treatment.Results: GKB extract significantly decreased blood HbA1c (7.7%±1.2% vs baseline 8.6%±1.6%, P |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896648/pdf https://www.dovepress.com/getfile.php?fileID=41359 |
| Ending Page | 742 |
| Page Count | 8 |
| Starting Page | 735 |
| e-ISSN | 11778881 |
| DOI | 10.2147/dddt.s157113 |
| Journal | Drug design, development and therapy |
| Volume Number | 12 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2018-04-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Drug Design, Development and Therapy Integrative and Complementary Medicine Bmi Ginkgo Biloba Extract T2dm Glycemic Control Insulin Resistance Metformin |
| Content Type | Text |
| Resource Type | Article |
